Atlas Trials

Essen Biotech

17 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Essen Biotech

RecordFirmDate
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors (NCT07410676)Essen Biotech2026-02-01
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors (NCT07410494)Essen Biotech2026-02-01
Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas (NCT07066982)Essen Biotech2025-05-29
Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer (NCT07066995)Essen Biotech2025-04-29
Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer (NCT07067255)Essen Biotech2025-04-29
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma (NCT07032129)Essen Biotech2025-04-29
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas (NCT06640582)Essen Biotech2024-10-20
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer (NCT06530303)Essen Biotech2024-09-29
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer (NCT06532799)Essen Biotech2024-09-10
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer (NCT06532812)Essen Biotech2024-08-22
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer (NCT06538012)Essen Biotech2024-08-20
Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease (NCT06399107)Essen Biotech2024-08-01
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells (NCT06420076)Essen Biotech2024-07-10
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML (NCT06420063)Essen Biotech2024-07-10
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (NCT06213636)Essen Biotech2024-07-10
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) (NCT06350110)Essen Biotech2024-07-10
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases (NCT06428188)Essen Biotech2024-05-29

Track Essen Biotech automatically

Every clearance here is in the API, with alerts when new ones post.